| Title: |
Anti-aminoacyl tRNA synthetase antibodies showing the discrepancy between enzyme-linked immunosorbent assay and RNA-immunoprecipitation. |
| Authors: |
Sasai, Tsuneo, Ishikawa, Yuki, Nakashima, Ran, Isayama, Takuya, Tanizawa, Kiminobu, Handa, Tomohiro, Shirakashi, Mirei, Hiwa, Ryosuke, Tsuji, Hideaki, Kitagori, Koji, Akizuki, Shuji, Yoshifuji, Hajime, Mimori, Tsuneyo, Morinobu, Akio |
| Source: |
Immunological Medicine; Sep2024, Vol. 47 Issue 3, p166-175, 10p |
| Subject Terms: |
ENZYME-linked immunosorbent assay, INTERSTITIAL lung diseases, OVERALL survival, WESTERN immunoblotting, DERMATOMYOSITIS |
| Abstract: |
Anti-aminoacyl-tRNA synthetase (ARS) antibodies are myositis-specific antibodies associated with anti-synthetase syndrome (ASSD). Some patients are positive for anti-ARS antibodies on enzyme-linked immunosorbent assay (ELISA) but negative on RNA-immunoprecipitation (RNA-IP) (the gold standard method). Whether these patients should be considered truly positive for anti-ARS antibodies remains unclear. Therefore, we investigated the clinical characteristics of these patients and verified the authenticity of their anti-ARS positivity. Patients who were positive for anti-ARS antibodies on ELISA were divided into the non-discrepant (positive on RNA-IP, n = 52) and discrepant (negative on RNA-IP, n = 8) groups. Patient clinical characteristics were compared between the groups. For each positive individual, the authenticity of anti-ARS antibody positivity on ELISA was cross-examined using protein-IP and western blotting. All patients in the discrepant group had lung involvement, including five (63%) with interstitial lung disease. The overall survival time was significantly lower in the discrepant group than in the non-discrepant group (p < 0.05). Validation tests confirmed the presence of anti-ARS antibodies in the sera of the discrepant group but indicated different reactivity from typical anti-ARS antibodies. In conclusion, some anti-ARS antibodies are detected by ELISA but not RNA-IP. Such anti-ARS antibody discrepancies need further elucidation to attain validation of the diagnostic process in ASSD. [ABSTRACT FROM AUTHOR] |
|
Copyright of Immunological Medicine is the property of Taylor & Francis Ltd and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) |
| Database: |
Complementary Index |
